Identification of Disease Biomarkers by Profiling of Serum Proteins Using SELDI-TOF Mass Spectrometry
Proteins are the main actors in all physiological and pathological processes. Since the final structure of the protein does not depend on the DNA sequence or even the mRNA sequence alone, the search for direct approaches on the proteome has gained great interest. The most complex and probably the largest proteome is serum, making it clinically the most important.
ProteinChip technology, in combination with modern mass spectrometry, allows the complex search for biomarkers, molecular interactions, signaling pathways, and the identification of novel therapeutic compounds. Here we describe the surface-enhanced laser desorption-ionization (SELDI) in combination with the time-of-flight (TOF) mass spectrometry for analyzing serum samples (SELDI was a patented technique from Ciphergen, Fremont, CA). Aluminum-based arrays contain chemical or biological surfaces allowing the capture of proteins, which interact with the surface. The bound proteins are laser desorbed and ionized for mass spectroscopy analysis. The differential mass spectral patterns reflect the protein expression bound on the chip surface and allow the comparison between various samples. Proteins of interest can be identified using peptide mass fingerprinting (PME).
KeywordsSurface-enhanced laser desorption-ionization (SELDI) time of flight (TOF) mass spectrometry (MS) serum ProteinChip fractionated serum biomarker peptide mass fingerprinting (PMF)
I thank Dr. R. Bogumil for his helpful advice and constructive criticism.
- 5.Wiesner A (2004) Detection of tumor markers with ProteinChip technology Curr Pharm Biotechnol 5:45–67Google Scholar
- 8.8. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright G L Jr, Drake RR, Vlahou A (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100:1814–1822CrossRefPubMedGoogle Scholar
- 10.Yip TT, Lomas L (2002) SELDI ProteinChip array in oncoproteomic research Technol Cancer Res Treat 1:273–280Google Scholar